Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Larimar Therapeutics (ZA71) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Nomlabofusp, Cti-1601Friedreich Ataxia, Friedreich's AtaxiaPhase IIIRecruitingA Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaAug 17, 2026
NomlabofuspFriedreich AtaxiaPhase ITerminatedA Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's AtaxiaNov 06, 2024
Cti-1601, NomlabofuspFriedreich AtaxiaPhase IIRecruitingAn Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaFeb 15, 2024―
Cti-1601Friedreich AtaxiaPhase IICompletedA Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaOct 05, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Larimar Therapeutics, Inc. (DE:ZA71) have in its pipeline
Larimar Therapeutics DE:ZA71 is currently developing the following drugs: Nomlabofusp, Cti-1601, Nomlabofusp, Cti-1601, Nomlabofusp, Cti-1601. These drug candidates are in various stages of clinical development as the company works toward FDA approval.